A 38-year-old male from rural Bihar with a history of incomplete TB treatment presents with persistent cough and sputum smear positivity after 4 months of standard first-line anti-TB therapy. Drug susceptibility testing confirms MDR-TB with resistance to isoniazid and rifampicin. All of the following are appropriate components of the MDR-TB treatment regimen EXCEPT:

Explanation

## MDR-TB Treatment Regimen: WHO 2023 Guidelines **Key Point:** MDR-TB treatment requires a carefully structured regimen combining drugs from different groups (A, B, C) with proven efficacy. Streptomycin is NOT recommended in modern MDR-TB regimens due to high rates of cross-resistance with rifampicin. ### WHO-Recommended MDR-TB Regimen Structure **Intensive Phase (20 months total; 8 months intensive):** - **Group A (Core agents):** Fluoroquinolone + Bedaquiline + Linezolid - **Group B (Add-on):** Injectable agent (amikacin or capreomycin) - **Group C (Supplementary):** Ethionamide/prothionamide, para-aminosalicylic acid (PAS) **Continuation Phase (12 months):** - Fluoroquinolone + Bedaquiline + Linezolid ± Group C agents ### Why Streptomycin is INCORRECT for MDR-TB **High-Yield:** Streptomycin is a first-line injectable agent used in **drug-susceptible TB**, NOT MDR-TB. In MDR-TB: 1. **Cross-resistance:** Rifampicin resistance mutations often confer streptomycin resistance (both target bacterial ribosomes) 2. **High resistance rates:** 30–50% of MDR-TB strains are already resistant to streptomycin 3. **Poor outcomes:** Using streptomycin in MDR-TB leads to treatment failure and further resistance 4. **WHO recommendation:** Amikacin or capreomycin are preferred injectables; streptomycin is explicitly NOT recommended **Warning:** Confusing first-line injectable agents (streptomycin) with second-line injectables (amikacin, capreomycin) is a frequent exam trap. ### Correct MDR-TB Components Explained | Component | Category | Role | Duration | |-----------|----------|------|----------| | Fluoroquinolone (levofloxacin/moxifloxacin) | Group A | Core bactericidal agent | 20 months | | Bedaquiline | Group A | Rapid bacterial kill, sterilizing activity | 20 months | | Linezolid | Group B | Bactericidal, especially for resistant strains | 20 months | | Amikacin or capreomycin | Group B | Injectable agent (intensive phase only) | 8 months | | Ethionamide/prothionamide | Group C | Supplementary agent | 20 months | | PAS (para-aminosalicylic acid) | Group C | Supplementary agent | 20 months | **Option 1 (Fluoroquinolone):** Correct. Fluoroquinolones (especially moxifloxacin) are core Group A agents with excellent lung penetration and are essential in all MDR-TB regimens. **Option 2 (Bedaquiline):** Correct. Bedaquiline is a Group A drug that inhibits ATP synthase, providing rapid and sustained bactericidal activity. It is a cornerstone of modern MDR-TB therapy. **Option 4 (Linezolid):** Correct. Linezolid is a Group B agent with strong bactericidal activity against *M. tuberculosis*, particularly useful in drug-resistant disease. It inhibits protein synthesis via the 50S ribosome. **Clinical Pearl:** The modern MDR-TB regimen (bedaquiline-containing) has cure rates >85% when adherence is ensured, compared to older streptomycin-based regimens with cure rates <50%.